Stay updated on Lorlatinib After First-line TKI Failure in ROS1 NSCLC Clinical Trial
Sign up to get notified when there's something new on the Lorlatinib After First-line TKI Failure in ROS1 NSCLC Clinical Trial page.

Latest updates to the Lorlatinib After First-line TKI Failure in ROS1 NSCLC Clinical Trial page
- Check4 days agoNo Change Detected
- Check11 days agoChange DetectedDifference12%
- Check19 days agoChange DetectedPage update: new date and study identifiers added (v3.1.0), replacing older date and revision (v3.0.2).SummaryDifference2%
- Check26 days agoNo Change Detected
- Check33 days agoChange DetectedVersion updated from v3.0.1 to v3.0.2. The only other visible change is the removal of the 'Back to Top' link, a minor UI cleanup with no substantive changes to content, pricing, stock, or time slots.SummaryDifference0.7%
- Check40 days agoChange DetectedThe web page has been updated from version 3.0.0 to version 3.0.1, indicating a revision in the content. There are no significant changes to core content, names, pricing, or availability.SummaryDifference0.7%
- Check47 days agoChange DetectedThe web page has undergone significant changes, including the addition of a facility name and location details, while several location-related terms have been removed.SummaryDifference13%
- Check61 days agoChange DetectedThe web page has been updated from version v2.16.11 to v2.16.12.SummaryDifference0.3%
Stay in the know with updates to Lorlatinib After First-line TKI Failure in ROS1 NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Lorlatinib After First-line TKI Failure in ROS1 NSCLC Clinical Trial page.